AGP Executive Report
Last update: 10 hours agoHemp Policy Showdown: U.S. Sen. Katie Britt says she’ll keep fighting a “dangerous loophole” that lets hemp-derived THC products reach children, as the Senate vote delays closing the gap by about a month—keeping many THC gummies, vapes, and smokables on shelves longer. Federal Ban Pressure: Multiple reports point to a looming Nov. 12 federal restriction that could effectively shut down many hemp-derived cannabinoid products, with industry groups warning it would devastate farmers and small businesses. Regulatory Pushback in States: Pennsylvania’s AG is urging Congress to let the federal overhaul take effect, arguing it would clarify enforcement for “intoxicating products,” while hemp advocates warn it could still shutter legitimate businesses. Clinical CBD/Canabinoid Pipeline: Artelo Biosciences enrolled its first patient in a Phase 2 glaucoma study of ART27.13, a peripherally selective synthetic cannabinoid receptor agonist aimed at lowering eye pressure with fewer central side effects. Company Updates: MediPharm Labs set Aug. 13 for Q2 2026 financial results, underscoring continued investment in pharmaceutical-grade cannabinoid concentrates. Local Enforcement Politics: Houston is set to vote on a ballot measure to make low-level marijuana possession the lowest enforcement priority and to ban no-knock warrants.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
